Servier takes NICE to court over Protelos guidance
This article was originally published in Scrip
Executive Summary
Servierhas asked an English court for a judicial review of theNational Institute for health and Clinical Excellence's guidance on the primary and secondary prevention of osteoporotic fractures in elderly women. The company is challenging the guidance because it believes that access to its Protelos (strontium ranelate) is being restricted unnecessarily and unfairly for many patients who could benefit from it.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.